ABZORVE Trademark

Trademark Overview

On Wednesday, February 27, 2019, a trademark application was filed for ABZORVE with the United States Patent and Trademark Office. The USPTO has given the ABZORVE trademark a serial number of 79255122. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Thursday, November 7, 2024. This trademark is owned by Glaxo Group Limited. The ABZORVE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines

General Information

Serial Number79255122
Word MarkABZORVE
Filing DateWednesday, February 27, 2019
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateThursday, November 7, 2024
Registration Number5905897
Registration DateTuesday, November 12, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 27, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateThursday, November 7, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW8 9GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW8 9GS
GB

Trademark Events

Event DateEvent Description
Tuesday, April 2, 2019APPLICATION FILING RECEIPT MAILED
Thursday, March 21, 2019SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Wednesday, March 27, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 3, 2019ASSIGNED TO EXAMINER
Monday, April 8, 2019NON-FINAL ACTION WRITTEN
Tuesday, April 9, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, April 30, 2019REFUSAL PROCESSED BY MPU
Tuesday, April 30, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 17, 2019REFUSAL PROCESSED BY IB
Friday, July 12, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 18, 2019ASSIGNED TO LIE
Thursday, July 18, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 18, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 23, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 7, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 7, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 7, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, August 23, 2019NOTIFICATION PROCESSED BY IB
Tuesday, August 27, 2019PUBLISHED FOR OPPOSITION
Tuesday, August 27, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 12, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, March 3, 2020FINAL DISPOSITION PROCESSED
Wednesday, February 12, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, July 19, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Tuesday, March 3, 2020FINAL DISPOSITION NOTICE SENT TO IB
Friday, March 20, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, August 1, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Monday, August 1, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 1, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 1, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 23, 2025DEATH OF INTERNATIONAL REGISTRATION
Friday, May 23, 2025NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Tuesday, November 12, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

Related Keywords

abzorve pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological